Tin tức & Cập nhật
Lọc theo Chuyên ngành:
Palbociclib–bazedoxifene combo for HR+/HER2− breast cancer succeeds in early trial
Treatment with the combination of palbociclib plus bazedoxifene demonstrates clinical efficacy while having an acceptable safety profile in treatment-experienced patients with hormone receptor–positive/HER2-negative (HR+/HER2−) advanced breast cancer, according to the results of a phase Ib/II study.
Palbociclib–bazedoxifene combo for HR+/HER2− breast cancer succeeds in early trial
14 Dec 2022
Acalabrutinib-based chemo-free triplet shows high rates of MRD-negative CR in 1L MCL study
First-line (1L) acalabrutinib in combination with lenalidomide and rituximab (ALR) has demonstrated high rates of minimal residual disease (MRD)–negative complete remission (CR) in patients with mantle cell lymphoma (MCL), including patients with TP53 mutations, in a single-arm phase II trial reported at the 64th American Society of Hematology (ASH) Annual Meeting and Exposition.
Acalabrutinib-based chemo-free triplet shows high rates of MRD-negative CR in 1L MCL study
14 Dec 2022
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
A large genomic study involving 1,016 Chinese patients with prostate cancer has revealed important differences in castration-sensitive disease between Chinese and Caucasian patients, but the mutation profile of metastatic castration-resistant prostate cancer (mCRPC) is similar between the populations.
Prostate cancer genomic study shows disparity between Chinese and Caucasians with castration-sensitive disease
13 Dec 2022
Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib
The MET inhibitor tepotinib demonstrates clinically meaningful antitumour activity, with durable efficacy and manageable safety profile in Asian nonsmall cell lung cancer (NSCLC) patients with MET mutations associated with exon 14 skipping, as shown in the subset analysis of the single-arm, phase II VISION study.
Asians with MET exon 14 skipping NSCLC achieve durable response with tepotinib
12 Dec 2022
Amivantamab/lazertinib combo shows promise in EGFR-mutated NSCLC
Among nonsmall cell lung cancer (NSCLC) patients with mutations spanning exons 18 to 21, combination treatment with amivantamab and lazertinib induces high rates of response, reports a study presented at the recent 2022 European Society for Medical Oncology Asia Congress (ESMO Asia 2022).
Amivantamab/lazertinib combo shows promise in EGFR-mutated NSCLC
10 Dec 2022
ALESIA: Long-term data support first-line alectinib in Asians with ALK-positive NSCLC
First-line treatment with alectinib appears to produce sustained clinical benefit in Asian patients with advanced, ALK-positive nonsmall cell lung cancer (NSCLC) through 5 years of follow-up, according to long-term data from the phase III ALESIA presented at the ESMO Asia Congress 2022.